© Copyright Our Wall
The vaccine
adjuvants marketis estimated to be worth $4.3
billion in 2022 and is expected to grow at compounded annual growth rate (CAGR)
of 2.7% during the forecast period.
Vaccines have enabled the
prevention of more than 37 million deaths due to various disease indications,
such as cholera, diphtheria, influenza, tetanus, whooping cough and measles,
between 2000 to 2019. Given the rate at
which the global population is growing and taking into consideration the
prevalent (such as the COVID-19 pandemic) and anticipated future trends, the
demand for vaccines is likely to increase significantly. According to experts,
the global vaccines market is anticipated to generate revenues worth USD 100
billion by 2025. In this regard, significant strides have been made to develop
safe and effective, next generation vaccine candidates, such as sub-unit
vaccines, recombinant vaccines, conjugate vaccines and DNA vaccines. However,
such vaccines employ purified non-living vaccine antigens (unlike their
counterparts, live attenuated and inactivated vaccines) and are, most often,
less immunogenic and require an additional aid to increase their immunogenicity
against the target antigens. As a result, a variety of vaccine adjuvants
(substances with the innate potential to augment an immune response), such as
AS04 (Cervarix®), MF59 (Fluad®), AS01B (Shingrix®) and CpG 1018 (Heplisav-B®),
have been discovered and are now available for the development of more
effective and versatile vaccine formulations.
Presently, an increasing number of
vaccines under development are incorporating vaccine adjuvants owing to various
advantages offered by such agents, including improved adaptive response to a
vaccine, guiding the type of adaptive response to produce the most effective
forms of immunity for each specific pathogen and facilitation of the use of
smaller doses of antigen. Further,
majority of the adjuvants used in human vaccines enhance humoral immunity;
however, several novel adjuvants in clinical or preclinical development are
focused on enhancing specific types of T-cell responses to generate
multifaceted immune responses required for complex indications, such as malaria
and HIV-AIDS. Currently, more than 70 companies and academic / research
institutes are engaged in the development of various types of vaccine
adjuvants. It is worth highlighting that capital investments worth over USD 5.5
billion have been made by various private and public sector investors during
the last five years to fund the product development activity in this domain. In
addition, there have been several recently reported instances of collaborations
between industry / academic stakeholders to advance the development of various
vaccine adjuvants. Driven by the increasing demand for safe and effective
vaccines, ongoing pace of innovation in this field and financial support from
the investors, the vaccine adjuvants market is likely to witness substantial
growth in the mid to long-term.
Vaccine Adjuvant Developers – Current
Market Landscape
The continuously growing
pharmaceutical industry and demand for safe and effective vaccines amidst the
pandemic has led to an increase in the development of vaccine adjuvants. As a
result, vaccine developers are trying to incorporate vaccine adjuvants with
their respective product to increase its efficacy and efficiency. Moreover,
vaccine adjuvants play an important role in improving adaptive response to a
vaccine, guiding the type of adaptive response to produce the most effective
forms of immunity for each specific pathogen and facilitation of the use of
smaller doses of antigen. During our research, we identified more than 70
companies that are actively involved in developing close to 110 vaccine
adjuvants.
Thank you for reading our report. Kindly get in touch with us to know more
about the report or to receive a customized copy of it. Our team will ensure
the report is tailored according to your needs.
To view more details on this
report, click on the link
https://www.rootsanalysis.com/reports/metabolomics-services-market.html
About Roots Analysis
Roots Analysis is a global leader
in the pharma / biotech market research. Having worked with over 750 clients
worldwide, including Fortune 500 companies, start-ups, academia, venture
capitalists and strategic investors for more than a decade, we offer a highly
analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights.
We specialise in analysing areas
which have lacked quality research so far or require more focused understanding
within the broader industry. All our reports are structured in a way to enable
the reader develop a thorough perspective on the given subject. Apart from
writing reports on identified areas, we also provide bespoke research /
consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by
a global team. The leadership team brings a wealth of experience within the
sector. Their collective experience in pharmaceutical / affiliated domains
allows us to tackle various areas of research in a structured way. We also
regularly leverage our global network of experts who hold senior leadership
positions in reputed firms and organisations worldwide.
Contact Details
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Website: https://www.rootsanalysis.com/
The Wall